Adverse events associated with peanut oral immunotherapy in children - a systematic review and meta-analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 01 2020
20 01 2020
Historique:
received:
27
08
2019
accepted:
17
12
2019
entrez:
22
1
2020
pubmed:
22
1
2020
medline:
1
12
2020
Statut:
epublish
Résumé
While peanut oral immunotherapy (POIT) represents a promising treatment for peanut allergies in children, safety concerns remain a common barrier to widespread adoption. We aimed to systematically assess available evidence to determine the risk and frequency of adverse events occurring during POIT, and examine study-level characteristics associated with their occurrence and severity. A systematic search of MEDLINE, EMBASE, and Web of Science was conducted through April 2019. Controlled and non-controlled studies evaluating POIT were eligible. Twenty-seven studies, involving 1488 subjects, were included. Adverse events to POIT were common and led to treatment discontinuation in 6.6% of children (95% CI 4.4-9.0; 27 studies, I
Identifiants
pubmed: 31959857
doi: 10.1038/s41598-019-56961-3
pii: 10.1038/s41598-019-56961-3
pmc: PMC6971009
doi:
Substances chimiques
Allergens
0
Epinephrine
YKH834O4BH
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
659Références
Osborne, N. J. et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 127, 668–676 (2011).
pubmed: 21377036
doi: 10.1016/j.jaci.2011.01.039
pmcid: 21377036
Soller, L. et al. Overall prevalence of self-reported food allergy in Canada. J Allergy Clin Immunol 130, 986–988 (2012).
pubmed: 22867693
doi: 10.1016/j.jaci.2012.06.029
pmcid: 22867693
Nwaru, B. I. et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy 69, 992–1007, https://doi.org/10.1111/all.12423 (2014).
doi: 10.1111/all.12423
pubmed: 24816523
pmcid: 24816523
Nicolaou, N. et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 125, 191–197 (2010).
pubmed: 20109746
doi: 10.1016/j.jaci.2009.10.008
pmcid: 20109746
Sicherer, S. H. & Sampson, H. A. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 133, 291–307 (2014).
pubmed: 24388012
doi: 10.1016/j.jaci.2013.11.020
pmcid: 24388012
Anagnostou, K. & Clark, A. The management of peanut allergy. Arch Dis Child 100, 68–72 (2015).
pubmed: 25157179
doi: 10.1136/archdischild-2014-306152
pmcid: 25157179
Yu, J. W. et al. Accidental ingestions in children with peanut allergy. J Allergy Clin Immunol 118, 466–472 (2006).
pubmed: 16890773
doi: 10.1016/j.jaci.2006.04.024
pmcid: 16890773
Ewan, P. W. & Clark, A. T. Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan. Lancet 357, 111–115 (2001).
pubmed: 11197398
doi: 10.1016/S0140-6736(00)03543-1
pmcid: 11197398
Sicherer, S. H., Burks, A. W. & Sampson, H. A. Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics 102, e6 (1998).
pubmed: 9651458
doi: 10.1542/peds.102.1.e6
pmcid: 9651458
Bock, S. A. & Atkins, F. M. The natural history of peanut allergy. J Allergy Clin Immunol 83, 900–904 (1989).
pubmed: 2715549
doi: 10.1016/0091-6749(89)90103-6
pmcid: 2715549
Sicherer, S. H., Noone, S. A. & Munoz-Furlong, A. The impact of childhood food allergy on quality of life. Ann Allergy Asthma Immunol 87, 461–464 (2001).
pubmed: 11770692
doi: 10.1016/S1081-1206(10)62258-2
pmcid: 11770692
Chu, D. K. et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 393, 2222–2232 (2019).
pubmed: 31030987
doi: 10.1016/S0140-6736(19)30420-9
pmcid: 31030987
Nurmatov, U. et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 72, 1133–1147 (2017).
pubmed: 28058751
doi: 10.1111/all.13124
pmcid: 28058751
Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700, https://doi.org/10.1136/bmj.b2700 (2009).
doi: 10.1136/bmj.b2700
pubmed: 2714672
pmcid: 2714672
Freeman, M. F. & Tukey, J. W. Transformations related to the angular and the square root. The Annals of Mathematical Statistics, 607–611 (1950).
Nyaga, V. N., Arbyn, M. & Aerts, M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72, 39 (2014).
pubmed: 25810908
pmcid: 4373114
doi: 10.1186/2049-3258-72-39
Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J Stat Softw 36, 1–48 (2010).
doi: 10.18637/jss.v036.i03
Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634 (1997).
pubmed: 9310563
pmcid: 2127453
doi: 10.1136/bmj.315.7109.629
Anagnostou, K. et al. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 41, 1273–1281 (2011).
pubmed: 21414048
doi: 10.1111/j.1365-2222.2011.03699.x
Anagnostou, K. et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 383, 1297–1304 (2014).
pubmed: 24485709
pmcid: 4255069
doi: 10.1016/S0140-6736(13)62301-6
Bird, J. A. et al. Modified peanut oral immunotherapy protocol safely and effectively induces desensitization. J Allergy Clin Immunol Pract 3, 433–435 (2015).
pubmed: 25609341
doi: 10.1016/j.jaip.2014.11.020
Bird, J. A. et al. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. J Allergy Clin Immunol Pract 6, 476–485 (2018).
pubmed: 29092786
doi: 10.1016/j.jaip.2017.09.016
pmcid: 29092786
Blumchen, K. et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 126, 83–91 (2010).
pubmed: 20542324
doi: 10.1016/j.jaci.2010.04.030
pmcid: 20542324
Blumchen, K. et al. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy. J Allergy Clin Immunol Pract 7, 479–491 (2019).
pubmed: 30423449
doi: 10.1016/j.jaip.2018.10.048
pmcid: 30423449
Fauquert, J. L. et al. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study). Clin Exp Allergy 48, 862–874 (2018).
pubmed: 29665158
doi: 10.1111/cea.13148
pmcid: 29665158
Hofmann, A. M. et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 124, 286–291 (2009).
pubmed: 19477496
pmcid: 2731305
doi: 10.1016/j.jaci.2009.03.045
Howe, L. C. et al. Changing Patient Mindsets about Non-Life-Threatening Symptoms During Oral Immunotherapy: A Randomized Clinical Trial. J Allergy Clin Immunol Pract 7, 1550–1559 (2019).
pubmed: 30682576
doi: 10.1016/j.jaip.2019.01.022
pmcid: 30682576
Jones, S. M. et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124, 292–300 (2009).
pubmed: 19577283
pmcid: 2725434
doi: 10.1016/j.jaci.2009.05.022
Uotila, R., Kukkonen, A. K., Greco, D., Pelkonen, A. S. & Makela, M. J. Peanut oral immunotherapy decreases IgE to Ara h 2 and Ara h 6 but does not enhance sensitization to cross-reactive allergens. J Allergy Clin Immunol 139, 1393–1396 (2017).
pubmed: 27916627
doi: 10.1016/j.jaci.2016.09.054
pmcid: 27916627
MacGinnitie, A. J. et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 139, 873–881 (2017).
pubmed: 27609658
doi: 10.1016/j.jaci.2016.08.010
pmcid: 27609658
Nachshon, L., Goldberg, M. R., Katz, Y., Levy, M. B. & Elizur, A. Long-term outcome of peanut oral immunotherapy-Real-life experience. Pediatr Allergy Immunol 29, 519–526 (2018).
pubmed: 29698554
doi: 10.1111/pai.12914
pmcid: 29698554
Nagakura, K. I. et al. Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy. Int Arch Allergy Immunol 175, 181–188 (2018).
pubmed: 29339650
doi: 10.1159/000486310
pmcid: 29339650
Nagakura, K. I. et al. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan. Pediatr Allergy Immunol 29, 512–518 (2018).
pubmed: 29603410
doi: 10.1111/pai.12898
pmcid: 29603410
Narisety, S. D. et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol 135, 1275–1282 (2015).
pubmed: 25528358
doi: 10.1016/j.jaci.2014.11.005
pmcid: 25528358
Nozawa, A., Okamoto, Y., Moverare, R., Borres, M. P. & Kurihara, K. Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy. Pediatr Allergy Immunol 25, 323–328 (2014).
pubmed: 24953293
doi: 10.1111/pai.12243
pmcid: 24953293
Palisade Group of Clinical Investigators. et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med 379, 1991–2001 (2018).
doi: 10.1056/NEJMoa1812856
Reier-Nilsen, T. et al. Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy. Allergy 74, 337–348 (2019).
pubmed: 30225844
doi: 10.1111/all.13604
pmcid: 30225844
Schneider, L. C. et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 132, 1368–1374 (2013).
pubmed: 24176117
pmcid: 4405160
doi: 10.1016/j.jaci.2013.09.046
Tang, M. L. et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol 135, 737–744 e738, https://doi.org/10.1016/j.jaci.2014.11.034 (2015).
doi: 10.1016/j.jaci.2014.11.034
pubmed: 25592987
Tao, B. et al. Sequential hypoallergenic boiled peanut and roasted peanut oral immunotherapy. Clin Exp Allergy 47, 1501–1504, https://doi.org/10.1111/cea.13024 (2017).
doi: 10.1111/cea.13024
pubmed: 28873242
pmcid: 28873242
Varshney, P. et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127, 654–660 (2011).
pubmed: 21377034
pmcid: 3060783
doi: 10.1016/j.jaci.2010.12.1111
Vickery, B. P. et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol 139, 173–181 (2017).
pubmed: 27522159
doi: 10.1016/j.jaci.2016.05.027
pmcid: 27522159
Wasserman, R. L. et al. Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients. J Allergy Clin Immunol Pract 7, 418–426 (2019).
pubmed: 29859333
doi: 10.1016/j.jaip.2018.05.023
pmcid: 29859333
Yu, G. P., Weldon, B., Neale-May, S. & Nadeau, K. C. The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial. Int Arch Allergy Immunol 159, 179–182 (2012).
pubmed: 22678151
pmcid: 3505766
doi: 10.1159/000336391
Zhong, Y., Chew, J. L., Tan, M. M. & Soh, J. Y. Efficacy and safety of oral immunotherapy for peanut allergy: a pilot study in Singaporean children. Asia Pac Allergy 9, e1, https://doi.org/10.5415/apallergy.2019.9.e1 (2019).
doi: 10.5415/apallergy.2019.9.e1
pubmed: 30740349
pmcid: 30740349
Virkud, Y. V. et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol 139, 882–888 (2017).
pubmed: 27609653
doi: 10.1016/j.jaci.2016.07.030
pmcid: 27609653
Vander Leek, T. K., Liu, A. H., Stefanski, K., Blacker, B. & Bock, S. A. The natural history of peanut allergy in young children and its association with serum peanut-specific IgE. J Pediatr 137, 749–755 (2000).
doi: 10.1067/mpd.2000.109376